Fibroblast growth factor 23 and outcomes of atrial fibrillation: from clinical association to genetic evidence - Summary - MDSpire

Fibroblast growth factor 23 and outcomes of atrial fibrillation: from clinical association to genetic evidence

  • By

  • Jiaju Li

  • Yiwei Lai

  • Chao Jiang

  • Mingxiao Li

  • Zejun Yang

  • Manlin Zhao

  • Xiaodong Peng

  • Sitong Li

  • Qifan Li

  • Jiawei Chen

  • Zhen Wang

  • Suhui Zhang

  • Changsheng Ma

  • Jianzeng Dong

  • January 29, 2025

  • 0 min

Share

Objective:

To investigate the prognostic value of Fibroblast Growth Factor 23 (FGF23) in atrial fibrillation (AF) patients and its associations with clinical outcomes and genetic insights.

Key Findings:
  • Elevated serum FGF23 levels are associated with a 37% increase in all-cause mortality, a 40% increase in cardiovascular mortality, and a 43% increase in heart failure risk per standard deviation.
  • Increased PGSFGF23 is linked to a reduced risk of heart failure but an increased risk of all-cause mortality and ischaemic stroke, highlighting a complex relationship.
Interpretation:

FGF23 may serve as a potential biomarker for assessing AF-related outcomes, indicating a complex relationship between serum and genetic FGF23 levels that warrants further investigation.

Limitations:
  • The study is observational and cannot establish causation.
  • Potential confounding factors, such as specific comorbidities and lifestyle factors, were not fully accounted for in the analysis.
Conclusion:

FGF23 shows promise as a prognostic marker in AF patients, warranting further investigation into its underlying mechanisms.

Original Source(s)

Fibroblast growth factor 23 and outcomes of atrial fibrillation: from clinical association to genetic evidence

  • by Jiaju Li, Yiwei Lai, Chao Jiang, Mingxiao Li, Zejun Yang, Manlin Zhao, Xiaodong Peng, Sitong Li, Qifan Li, Jiawei Chen, Zhen Wang, Suhui Zhang, Changsheng Ma, Jianzeng Dong

  • January 29, 2025

Related Content